Alpha Therapeutic Corporation

Advanced Minerals Corporation

John Mark Rolf

Prabir Bhattacharya

Shawn D Latham

T (Tom) Taniguchi

Akimasa Ohmizu

Yahiro (Roy) Uemura

Provided are methods for substantially removing organic substances from an aqueous solution, wherein the aqueous solution is contacted with a synthetic hydrated calcium silicate. Components that can be removed from aqueous solution include bacterial, plant, algal and fungal components. Exemplary components include endotoxins. The aqueous solution comprises, for example, water, a chemically buffered solution, a pharmaceutical solution, a solution comprising a nutritional supplement, a culture medium, or a growth medium. Other examples include pharmaceutical compendial water and non-compendial water. In one embodiment of the method, the pH of the aqueous solution is maintained at a selected pH to promote the separation, for example, about pH 5.5 to 9.5, or, e.g., about pH 5.5 to 7.5.

Methods for the removal of organic substances from aqueous solutions

The present invention is directed to a process for purifying &agr;,-proteinase inhibitor. The process comprises providing an impure protein fraction which comprises &agr;,-proteinase inhibitor. The impure protein fraction is precipitated with a precipitant comprising PEG. The supernatant from the PEG precipitation, which comprises &agr;,-proteinase inhibitor, is collected and applied to an anion-exchange medium. A fraction comprising &agr;,-proteinase inhibitor is recovered from the anion-exchange medium and applied to a metal chelate medium. A fraction comprising &agr;,-proteinase inhibitor is then recovered from the metal chelate medium. Alpha,-proteinase inhibitor purified by the process has a specific activity greater than 0.6 units/mg.

Process for separating &agr;1-proteinase inhibitor from cohn fraction IV1 and IV4 paste

Method for obtaining highly purified transferrin from a partially purified plasma fraction containing transferrin in which the starting fraction is concentrated. Its ionic strength is reduced and then transferrin is adsorbed onto a chromatographic column. Following elution, the transferrin can be further processed through to packaging in final containers. The final purified transferrin product is sterile, at least 95% pure and is substantially free of enveloped and non-enveloped viruses.

Growing community of inventors

Los Angeles, CA, United States of America

John Mark Rolf